EA201200119A1 - Гетероциклические соединения в качестве ингибиторов аутотаксина - Google Patents

Гетероциклические соединения в качестве ингибиторов аутотаксина

Info

Publication number
EA201200119A1
EA201200119A1 EA201200119A EA201200119A EA201200119A1 EA 201200119 A1 EA201200119 A1 EA 201200119A1 EA 201200119 A EA201200119 A EA 201200119A EA 201200119 A EA201200119 A EA 201200119A EA 201200119 A1 EA201200119 A1 EA 201200119A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compounds
autotaxin inhibitors
autotaxin
inhibitors
compounds
Prior art date
Application number
EA201200119A
Other languages
English (en)
Russian (ru)
Inventor
Мелани Шультц
Кай Шиманн
Вольфганг Штэле
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201200119A1 publication Critical patent/EA201200119A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201200119A 2009-07-16 2010-06-17 Гетероциклические соединения в качестве ингибиторов аутотаксина EA201200119A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009033392A DE102009033392A1 (de) 2009-07-16 2009-07-16 Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
PCT/EP2010/003661 WO2011006569A1 (de) 2009-07-16 2010-06-17 Heterocyclische verbindungen als autotaxin-inhibitoren

Publications (1)

Publication Number Publication Date
EA201200119A1 true EA201200119A1 (ru) 2012-07-30

Family

ID=42646326

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200119A EA201200119A1 (ru) 2009-07-16 2010-06-17 Гетероциклические соединения в качестве ингибиторов аутотаксина

Country Status (16)

Country Link
US (1) US20120115852A1 (cg-RX-API-DMAC7.html)
EP (1) EP2454258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012532901A (cg-RX-API-DMAC7.html)
KR (1) KR20120090031A (cg-RX-API-DMAC7.html)
CN (1) CN102471343A (cg-RX-API-DMAC7.html)
AR (1) AR077488A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010272922A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012000792A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768095A1 (cg-RX-API-DMAC7.html)
DE (1) DE102009033392A1 (cg-RX-API-DMAC7.html)
EA (1) EA201200119A1 (cg-RX-API-DMAC7.html)
IL (1) IL217466A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012000609A (cg-RX-API-DMAC7.html)
SG (1) SG177522A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011006569A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201124B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
ES2753163T3 (es) * 2012-09-25 2020-04-07 Hoffmann La Roche Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
US9630945B2 (en) 2012-12-19 2017-04-25 Novartis Ag Autotaxin inhibitors
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
TW201446768A (zh) * 2013-03-15 2014-12-16 Biogen Idec Inc S1p及/或atx調節劑
EP3046905A4 (en) 2013-09-17 2017-03-22 Pharmakea Inc. Vinyl autotaxin inhibitor compounds
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
EP3878848A1 (en) 2013-11-22 2021-09-15 Sabre Therapeutics LLC Autotaxin inhibiting indole compounds
CR20160290A (es) 2013-11-22 2016-09-28 Pharmakea Inc Inhibidores tetracíclicos de autotaxina
CA2923523A1 (en) * 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
JP6554481B2 (ja) * 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MD20160116A2 (ro) 2014-04-04 2017-04-30 X-Rx Discovery, Inc Inhibitori spirociclici substituiţi ai autotaxinei
JP6592008B2 (ja) * 2014-04-23 2019-10-16 エックス−アールエックス， インコーポレイテッド オートタキシンの置換ｎ−（２−アミノ）−２−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにｌｐａ依存性またはｌｐａ媒介性疾患の処置における使用
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN116059203A (zh) 2015-05-27 2023-05-05 赛博治疗有限责任公司 自分泌运动因子抑制剂及其用途
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物
EP3353181B1 (en) 2015-09-24 2021-08-11 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
CN112312787B (zh) * 2018-05-21 2023-02-17 株式会社爱世克私 文胸
WO2020040326A1 (ko) * 2018-08-23 2020-02-27 가천대학교 산학협력단 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
WO2020072456A1 (en) * 2018-10-02 2020-04-09 Case Western Reserve University Compounds for treating myelin related disorders
EP4476222A1 (en) * 2022-02-10 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Fused diazepines as agonists of the insulin-like 3 (insl3) peptide receptor rxfp2 and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
NZ512960A (en) * 1999-01-19 2004-01-30 Ortho Mcneil Pharm Inc Tricyclic benzodiazepines as vasopressin receptor antagonists
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
ES2234692T3 (es) * 1999-11-09 2005-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimetricas en asociacion con otro agente anti-canceroso para una utilizacion terapeutica en el tratamiento del cancer.

Also Published As

Publication number Publication date
SG177522A1 (en) 2012-02-28
AU2010272922A1 (en) 2012-03-08
CA2768095A1 (en) 2011-01-20
CN102471343A (zh) 2012-05-23
WO2011006569A1 (de) 2011-01-20
KR20120090031A (ko) 2012-08-16
DE102009033392A1 (de) 2011-01-20
IL217466A0 (en) 2012-02-29
ZA201201124B (en) 2012-11-28
BR112012000792A2 (pt) 2016-02-23
AR077488A1 (es) 2011-08-31
MX2012000609A (es) 2012-01-27
JP2012532901A (ja) 2012-12-20
US20120115852A1 (en) 2012-05-10
EP2454258A1 (de) 2012-05-23

Similar Documents

Publication Publication Date Title
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
EA201200653A1 (ru) Гетариламинохинолины
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
EA201201170A1 (ru) Гетариламинонафтиридины
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201300873A1 (ru) Производные 7-азаиндола
EA201300282A1 (ru) Производные триазолопиразина
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201000558A1 (ru) Производные имидазола
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
EA201401081A1 (ru) Циклические амиды в качестве ингибиторов метар-2
EA201000004A1 (ru) Производные 6-(пирролопиридинил)пиримидин-2-иламина и их применение для лечения злокачественного новообразования и спида
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
EA201100966A1 (ru) Производные пиридазинона
EA201270254A1 (ru) Производные 5-фторпиримидинона
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA201000549A1 (ru) Производные пиперидина и пиперазина
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
EA201000550A1 (ru) Производные тиазола
EA201171210A1 (ru) Производные оксадиазола
EA201301301A1 (ru) Производные тиазола